Literature DB >> 20851032

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.

Laure Brulhart, Michael J Nissen, Paola Chevallier, Cem Gabay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20851032     DOI： 10.1016/j.jbspin.2010.08.004

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  14 in total

1.  The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.

Authors:  M Fabris; L Quartuccio; C Fabro; S Sacco; S Lombardi; R Ramonda; D Biasi; D Punzi; S Adami; I Olivieri; F Curcio; S De Vita
Journal:  Pharmacogenomics J       Date:  2015-07-07       Impact factor: 3.550

2.  Mucosal inflammation in spondylarthritides: past, present, and future.

Authors:  Liesbet Van Praet; Filip Van den Bosch; Herman Mielants; Dirk Elewaut
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

Review 3.  Impact of biological therapy on spondyloarthritis.

Authors:  Nicola Maruotti; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2014-06-10       Impact factor: 2.953

Review 4.  Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.

Authors:  Michitaro Hayakawa; Keisuke Izumi; Misako Higashida-Konishi; Mari Ushikubo; Masako Tsukamoto; Kumiko Akiya; Kazuhiro Araki; Hisaji Oshima
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

Review 5.  Genetics of asthma susceptibility and severity.

Authors:  Rebecca E Slager; Gregory A Hawkins; Xingnan Li; Dirkje S Postma; Deborah A Meyers; Eugene R Bleecker
Journal:  Clin Chest Med       Date:  2012-07-07       Impact factor: 2.878

6.  Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.

Authors:  Fernando Kemta Lekpa; Cécile Poulain; Daniel Wendling; Martin Soubrier; Michel De Bandt; Jean Marie Berthelot; Philippe Gaudin; Eric Toussirot; Philippe Goupille; Thao Pham; Jérémie Sellam; Rémy Bruckert; Muriel Paul; Valérie Farrenq; Pascal Claudepierre
Journal:  Arthritis Res Ther       Date:  2012-03-09       Impact factor: 5.156

7.  The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.

Authors:  Gregory A Hawkins; Mac B Robinson; Annette T Hastie; Xingnan Li; Huashi Li; Wendy C Moore; Timothy D Howard; William W Busse; Serpil C Erzurum; Sally E Wenzel; Stephen P Peters; Deborah A Meyers; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2012-05-01       Impact factor: 14.290

8.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

9.  Pathological role of interleukin-6 in psoriatic arthritis.

Authors:  Atsushi Ogata; Atsushi Kumanogoh; Toshio Tanaka
Journal:  Arthritis       Date:  2012-10-11

Review 10.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.